<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H35FE584CE78B4189992DF906B06BA297" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>109 HR 3307 IH: Lupus Research, Education, Awareness, Communication, and Healthcare Amendments of 2005</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2005-07-14</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form> 
<distribution-code display="yes">I</distribution-code> 
<congress>109th CONGRESS</congress>
<session>1st Session</session>
<legis-num>H. R. 3307</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20050714">July 14, 2005</action-date> 
<action-desc><sponsor name-id="R000435">Ms. Ros-Lehtinen</sponsor> (for herself, <cosponsor name-id="B000490">Mr. Bishop of Georgia</cosponsor>, <cosponsor name-id="B001251">Mr. Butterfield</cosponsor>, <cosponsor name-id="C000380">Mrs. Christensen</cosponsor>, <cosponsor name-id="C001049">Mr. Clay</cosponsor>, <cosponsor name-id="C001061">Mr. Cleaver</cosponsor>, <cosponsor name-id="C000714">Mr. Conyers</cosponsor>, <cosponsor name-id="D000096">Mr. Davis of Illinois</cosponsor>, <cosponsor name-id="G000553">Mr. Al Green of Texas</cosponsor>, <cosponsor name-id="H000324">Mr. Hastings of Florida</cosponsor>, <cosponsor name-id="J000032">Ms. Jackson-Lee of Texas</cosponsor>, <cosponsor name-id="J000070">Mr. Jefferson</cosponsor>, <cosponsor name-id="J000284">Mrs. Jones of Ohio</cosponsor>, <cosponsor name-id="K000180">Ms. Kilpatrick of Michigan</cosponsor>, <cosponsor name-id="L000551">Ms. Lee</cosponsor>, <cosponsor name-id="M001137">Mr. Meeks of New York</cosponsor>, <cosponsor name-id="M001160">Ms. Moore of Wisconsin</cosponsor>, <cosponsor name-id="N000147">Ms. Norton</cosponsor>, <cosponsor name-id="O000159">Mr. Owens</cosponsor>, <cosponsor name-id="R000053">Mr. Rangel</cosponsor>, <cosponsor name-id="R000515">Mr. Rush</cosponsor>, <cosponsor name-id="S000185">Mr. Scott of Virginia</cosponsor>, <cosponsor name-id="T000193">Mr. Thompson of Mississippi</cosponsor>, <cosponsor name-id="W000187">Ms. Waters</cosponsor>, <cosponsor name-id="W000794">Ms. Watson</cosponsor>, <cosponsor name-id="W000784">Mr. Wynn</cosponsor>, <cosponsor name-id="W000314">Mr. Wexler</cosponsor>, <cosponsor name-id="E000179">Mr. Engel</cosponsor>, <cosponsor name-id="W001159">Ms. Wasserman Schultz</cosponsor>, <cosponsor name-id="L000562">Mr. Lynch</cosponsor>, <cosponsor name-id="M001148">Mr. Meek of Florida</cosponsor>, <cosponsor name-id="K000172">Mr. Kildee</cosponsor>, <cosponsor name-id="S001145">Ms. Schakowsky</cosponsor>, <cosponsor name-id="H000627">Mr. Hinchey</cosponsor>, <cosponsor name-id="B001227">Mr. Brady of Pennsylvania</cosponsor>, <cosponsor name-id="T000326">Mr. Towns</cosponsor>, <cosponsor name-id="C000191">Ms. Carson</cosponsor>, and <cosponsor name-id="F000262">Mr. Ford</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To amend the Public Health Service Act to enhance public and health professional awareness and understanding of lupus and to strengthen the Nation’s research efforts to identify the causes and cure of lupus.</official-title> 
</form> 
<legis-body id="HB658EB181BAA447D008C6BE4E540D431" style="OLC"> 
<section commented="no" display-inline="no-display-inline" id="HEC43D7B064EA44CB9DDA4FEA93CB5283" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Lupus Research, Education, Awareness, Communication, and Healthcare Amendments of 2005</short-title></quote>.</text></section> 
<section commented="no" display-inline="no-display-inline" id="H5D3C538F6FC4474DB9E9A2355F45F408" section-type="subsequent-section"><enum>2.</enum><header>Table of contents</header><text display-inline="no-display-inline">The table of contents for this Act is as follows:</text> 
<toc> 
<toc-entry bold="off" idref="HEC43D7B064EA44CB9DDA4FEA93CB5283" level="section">Sec. 1. Short title.</toc-entry> 
<toc-entry bold="off" idref="H5D3C538F6FC4474DB9E9A2355F45F408" level="section">Sec. 2. Table of contents.</toc-entry> 
<toc-entry bold="off" idref="HA9CAB7059E1F4A4FAA1BC496900A300" level="section">Sec. 3. Findings.</toc-entry> 
<toc-entry bold="off" idref="HBA17B1216A084F248C712D9DA99B0043" level="title">TITLE I—Expanding and Improving Research on Lupus</toc-entry> 
<toc-entry bold="off" idref="HFA7BC089AB034FFD8857669E162069E" level="section">Sec. 101. Expansion of lupus biomedical research.</toc-entry> 
<toc-entry bold="off" idref="HDE10554C7BA84E7D84851F0096B89ECA" level="section">Sec. 102. Strengthening lupus epidemiology; lupus study.</toc-entry> 
<toc-entry bold="off" idref="H3D7DF6820DA34860B3C8A9CC731CF427" level="title">TITLE II—Enhancing lupus awareness and education</toc-entry> 
<toc-entry bold="off" idref="H932C487CECD441C8B91F45AF736E9163" level="section">Sec. 201. Increasing public awareness and improving health professional education.</toc-entry></toc></section> 
<section commented="no" display-inline="no-display-inline" id="HA9CAB7059E1F4A4FAA1BC496900A300" section-type="subsequent-section"><enum>3.</enum><header>Findings</header><text display-inline="no-display-inline">Congress makes the following findings:</text> 
<paragraph commented="no" display-inline="no-display-inline" id="H375E6D1741C442818C01F37C618F2BF"><enum>(1)</enum><text display-inline="yes-display-inline">Lupus is a serious, complex, debilitating autoimmune disease that can cause inflammation and tissue damage to virtually any organ system in the body, including the skin, joints, other connective tissue, blood and blood vessels, heart, lungs, kidney, and brain.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HC6BBE7CE31E846BD93EA7D5BED8C1197"><enum>(2)</enum><text display-inline="yes-display-inline">The Lupus Foundation of America, Inc. estimates that approximately 1,500,000 to 2,000,000 Americans live with some form of lupus; lupus affects women 9 times more often than men and 80 percent of newly diagnosed cases of lupus develop among women of child-bearing age.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H7F8EC8D562274EEC831BE9527FE21BC1"><enum>(3)</enum><text display-inline="yes-display-inline">Lupus disproportionately affects women of color; it is 2 to 3 times more common among African-Americans, Hispanics, Asians, and Native Americans and is generally more prevalent in minority populations, a health disparity that remains unexplained. According to the Centers for Disease Control and Prevention, the rate of lupus mortality has increased since the late 1970s and is higher among older African-American women.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H78E597ABAA564665AD0942AA4DBB6B5D"><enum>(4)</enum><text display-inline="yes-display-inline">There have been no new drugs approved by the Food and Drug Administration specifically for lupus in nearly 40 years and while current treatments for the disease can be effective, they can lead to damaging side effects.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HDC956964D0024389912986AC6268244B"><enum>(5)</enum><text display-inline="yes-display-inline">The pain and fatigue associated with lupus can threaten people’s ability to live independently and make it difficult to maintain employment and lead normal lives. One in 5 people with lupus is disabled by the disease, and consequently receives support from government programs, including medicare, medicaid, social security disability, and social security supplemental income.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HD2F189F3E3B347BEBBE883731B8699A0"><enum>(6)</enum><text display-inline="yes-display-inline">The estimated average annual cost of medical treatment for an individual with lupus can range between $10,000 and $30,000; for people who have the most serious form of lupus, medical costs can greatly exceed this amount, causing a significant economic, emotional, and social burden to the entire family and to society.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HFDFEE38B3E714911B45817169FC97122"><enum>(7)</enum><text display-inline="yes-display-inline">More than <fraction>1/2</fraction> of the people with lupus suffer 4 or more years and visit 3 or more physicians before obtaining a diagnosis of lupus; early diagnosis of, and commencement of treatment for, lupus can prevent or reduce serious organ damage, disability, and death.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H5924568235314741A1EF72585729C87"><enum>(8)</enum><text display-inline="yes-display-inline">Despite the magnitude of lupus and its impact on individuals and families, health professional and public understanding of lupus remains low; only 1 of 5 Americans can provide even basic information about lupus, and awareness of lupus is lowest among adults ages 18 to 34, the age group most likely to develop symptoms of lupus.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HCBC45DE06A07469A99F132A54237F630"><enum>(9)</enum><text display-inline="yes-display-inline">Lupus is a significant national health issue that deserves a comprehensive and coordinated response by Federal and State governments with the involvement of the healthcare provider, patient, and public health communities.</text></paragraph></section> 
<title commented="no" id="HBA17B1216A084F248C712D9DA99B0043" style="OLC"><enum>I</enum><header>Expanding and Improving Research on Lupus</header> 
<section commented="no" display-inline="no-display-inline" id="HFA7BC089AB034FFD8857669E162069E" section-type="subsequent-section"><enum>101.</enum><header>Expansion of lupus biomedical research</header><text display-inline="no-display-inline">Section 441A of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/285d-6a">42 U.S.C. 285d–6a</external-xref>) is amended to read as follows:</text> 
<quoted-block act-name="" display-inline="no-display-inline" id="HFFE5386ADC2148D58900EF4305F64C47" style="traditional"> 
<section commented="no" display-inline="no-display-inline" id="HEFEF00CBF8C844F987C28E75006C008E" section-type="subsequent-section"><enum>441A.</enum><header>Expansion of lupus biomedical research</header> 
<subsection commented="no" display-inline="yes-display-inline" id="H968C383266624A46A9A5E5825E00A121"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary, acting through the Director of the Institute, shall expand and intensify research and related activities of the Institute with respect to lupus.</text></subsection> 
<subsection commented="no" display-inline="no-display-inline" id="HB48E7A895F014F6EA09903051200958E"><enum>(b)</enum><header>Coordination with other institutes</header><text display-inline="yes-display-inline">The Director of the Institute shall coordinate the activities of the Director under subsection (a) with similar activities conducted by the other national research institutes and agencies of the National Institutes of Health to the extent that such institutes and agencies have responsibilities that are related to lupus.</text></subsection> 
<subsection commented="no" display-inline="no-display-inline" id="H02BF314068764DE200AED4E564172026"><enum>(c)</enum><header>Programs for lupus</header><text display-inline="yes-display-inline">In carrying out subsection (a), the Director of the Institute shall conduct or support research to expand the understanding of the causes of, and to find a cure for, lupus. Activities under such subsection shall include conducting and supporting the following:</text> 
<paragraph commented="no" display-inline="no-display-inline" id="H1BCC72B96BC54E770082B347FB91EC0"><enum>(1)</enum><text display-inline="yes-display-inline">Basic research to discover the pathogenesis and pathophysiology of the disease.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HBAA5F49AEE954E76A6392EC4DB00E1C6"><enum>(2)</enum><text display-inline="yes-display-inline">Research to determine the reasons underlying the disproportionate prevalence of lupus in African-American, Hispanic, Native American, and Asian women.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HF1F613F8A8E34F1D821F2BDD73C4D2C3"><enum>(3)</enum><text display-inline="yes-display-inline">Epidemiological studies to address the frequency and natural history of the disease and the differences between the sexes and among racial and ethnic groups with respect to the disease.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H7011868DBA904E6EA18658C6BE84470"><enum>(4)</enum><text display-inline="yes-display-inline">Clinical research for the development and evaluation of new treatments, including new biological agents.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HCDDEA871F7E94FCE9BCABEB227563DA3"><enum>(5)</enum><text display-inline="yes-display-inline">Research to validate lupus biomarkers.</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H01359381245E4E619300957700E42C7E"><enum>(6)</enum><text display-inline="yes-display-inline">Research to develop improved diagnostic tests.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section> 
<section commented="no" display-inline="no-display-inline" id="HDE10554C7BA84E7D84851F0096B89ECA" section-type="subsequent-section"><enum>102.</enum><header>Strengthening lupus epidemiology; lupus study</header><text display-inline="no-display-inline">Part B of title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/243">42 U.S.C. 243 et seq.</external-xref>) is amended by inserting after section 318B the following:</text> 
<quoted-block act-name="" display-inline="no-display-inline" id="HD93E370C6F934596A6C6E9ABF76698A2" style="traditional"> 
<section commented="no" display-inline="no-display-inline" id="H8F377729F2F64D279B20D11249D0F9A8" section-type="subsequent-section"><enum>318C.</enum><header>Strengthening lupus epidemiology</header> 
<subsection commented="no" display-inline="yes-display-inline" id="HB6AA3774D4E343ACAAA4025CA7EDEBE5"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall work with a consortium of leading United States academic health institutions that have expertise in the epidemiology of lupus to undertake a national scale lupus epidemiological study to determine the true prevalence and incidence of lupus in the United States.</text></subsection> 
<subsection commented="no" display-inline="no-display-inline" id="H47245EE5A07849E48E95CCB885C13AE"><enum>(b)</enum><header>Use of funds</header><text display-inline="yes-display-inline">The Director of the Centers for Disease Control and Prevention shall enter into a cooperative agreement with the consortium described in subsection (a) to develop, implement, and manage a system for lupus data collection and analysis, including—</text> 
<paragraph commented="no" display-inline="no-display-inline" id="H7E6378A2DDAB4B4BB457A368BE54066E"><enum>(1)</enum><text display-inline="yes-display-inline">the creation and use of a common data entry and management system across all study sites; and</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HE1402D8516464E1790643B532F3FED98"><enum>(2)</enum><text display-inline="yes-display-inline">the enhancement of the 2 study sites involved in the existing lupus patient registry of the Centers for Disease Control and Prevention on the day before the date of enactment of the <short-title>Lupus Research, Education, Awareness, Communication, and Healthcare Amendments of 2005</short-title>.</text></paragraph></subsection> 
<subsection commented="no" display-inline="no-display-inline" id="HF83035208D7742C58B9B25D52B6B26D1"><enum>(c)</enum><header>Geographic representation</header><text display-inline="yes-display-inline">The Director of the Centers for Disease Control and Prevention shall ensure that the consortium described in subsection (a) represents different geographic regions of the United States that have a sufficient number of individuals of all racial and ethnic backgrounds disproportionately affected by lupus, including Hispanics, Asians, Native Americans, and African-Americans.</text></subsection> 
<subsection commented="no" display-inline="no-display-inline" id="H4A15628496254E3F98F3F1003BBDACF2"><enum>(d)</enum><header>Certain activities</header><text display-inline="yes-display-inline">In carrying out subsections (a) and (b), the consortium described in subsection (a) shall capture data related to all affected populations on all forms of lupus, including lupus related disorders.</text></subsection> 
<subsection commented="no" display-inline="no-display-inline" id="H5AFD66AD8DF6420682FF3550C3E035DE"><enum>(e)</enum><header>Authorization of appropriations</header><text display-inline="yes-display-inline">There are authorized to be appropriated to carry out this section $3,500,000 for each of the fiscal years 2006, 2007, 2008, and 2009.</text></subsection></section> 
<section commented="no" display-inline="no-display-inline" id="HB188B49476894E73A5DAC8DF6EA0B8BD" section-type="subsequent-section"><enum>318D.</enum><header>Lupus study and report by the Institute of Medicine</header> 
<subsection commented="no" display-inline="yes-display-inline" id="H87B16D5475D34CEB90E22DC62BA04376"><enum>(a)</enum><header>Contract</header><text display-inline="yes-display-inline">The Secretary shall enter into a contract with the Institute of Medicine to conduct a study—</text> 
<paragraph commented="no" display-inline="no-display-inline" id="H7F33350BBF9B40E0A0D0375BA35F6DAF"><enum>(1)</enum><text display-inline="yes-display-inline">to evaluate the Federal and State activities related to lupus research, education, and awareness programs and activities and make recommendations for ways in which these initiatives could be expanded;</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H3BA34840882F41F1ABD6C368323234CE"><enum>(2)</enum><text display-inline="yes-display-inline">to identify the gaps in Federal research related to—</text> 
<subparagraph commented="no" display-inline="no-display-inline" id="HDDB75BD4512B4316ACDD1900A0CEB17"><enum>(A)</enum><text display-inline="yes-display-inline">the causes of lupus;</text></subparagraph> 
<subparagraph commented="no" display-inline="no-display-inline" id="H65ADEA2FB2CA4DC49C895227035F9323"><enum>(B)</enum><text display-inline="yes-display-inline">lupus detection and diagnosis;</text></subparagraph> 
<subparagraph commented="no" display-inline="no-display-inline" id="HDBDCF5FED91249289FDDD1368E3CF5DB"><enum>(C)</enum><text display-inline="yes-display-inline">lupus treatment; and</text></subparagraph> 
<subparagraph commented="no" display-inline="no-display-inline" id="H0ADB595DB96D45AFB7FA8970481800AA"><enum>(D)</enum><text display-inline="yes-display-inline">lupus quality-of-life concerns;</text></subparagraph></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H2E23B0F4CD824BE5A375223650A68365"><enum>(3)</enum><text display-inline="yes-display-inline">to make recommendations for building and supporting the lupus research enterprise, including recommendations for strategies for future basic, clinical, social, and behavioral research—</text> 
<subparagraph commented="no" display-inline="no-display-inline" id="HC019870D709A4D099211008BD29BF604"><enum>(A)</enum><text display-inline="yes-display-inline">to determine the pathophysiology and pathogenesis of the disease; and</text></subparagraph> 
<subparagraph commented="no" display-inline="no-display-inline" id="H62A1BE6EE3A84D84B9E18FE220480090"><enum>(B)</enum><text display-inline="yes-display-inline">to secure the development of new and improved lupus therapies and ways to diagnose the disease;</text></subparagraph></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HD2749C19D7AE4946B8977415DABFC600"><enum>(4)</enum><text display-inline="yes-display-inline">to determine the gaps in lupus health professional education programs and public awareness efforts and make recommendations for ways in which the Federal Government can—</text> 
<subparagraph commented="no" display-inline="no-display-inline" id="H1A8F896DD2C44B33A925ADF1A852E19D"><enum>(A)</enum><text display-inline="yes-display-inline">improve public and health professional awareness of lupus; and</text></subparagraph> 
<subparagraph commented="no" display-inline="no-display-inline" id="HD62E88F68899412CA0932943E8F6AD65"><enum>(B)</enum><text display-inline="yes-display-inline">partner and support nonprofit voluntary health agencies (such as the Lupus Foundation of America, Inc.) and academic institutions and other interested stakeholders whose primary purposes are to increase public awareness of lupus and to improve the diagnosis and treatment of lupus;</text></subparagraph></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H6030987C51F94BF9B4642993562419DB"><enum>(5)</enum><text display-inline="yes-display-inline">to make recommendations regarding ways to improve the quality of life for people with lupus;</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H88EFDAA18B2B4719914D1DE03D065F04"><enum>(6)</enum><text display-inline="yes-display-inline">to summarize the clinical and biological features of lupus and the characteristics and management of major symptoms and make recommendations for disease management and measurement; and</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H53C2CB4610A04800854727040052ECFC"><enum>(7)</enum><text display-inline="yes-display-inline">to make recommendations for epidemiological studies in the various population groups affected by lupus in the United States.</text></paragraph></subsection> 
<subsection commented="no" display-inline="no-display-inline" id="H8B1F3BA1793F4B18A24055FF307D33D6"><enum>(b)</enum><header>Report</header><text display-inline="yes-display-inline">Not later than 18 months after the date of enactment of the <short-title>Lupus Research, Education, Awareness, Communication, and Healthcare Amendments of 2005</short-title>, the Institute of Medicine shall submit to the Secretary a report containing the information described in paragraphs (1) through (7) of subsection (a).</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section></title> 
<title commented="no" id="H3D7DF6820DA34860B3C8A9CC731CF427" style="OLC"><enum>II</enum><header>Enhancing lupus awareness and education</header> 
<section commented="no" display-inline="no-display-inline" id="H932C487CECD441C8B91F45AF736E9163" section-type="subsequent-section"><enum>201.</enum><header>Increasing public awareness and improving health professional education</header><text display-inline="no-display-inline">Part B of title III of the Public Health Service Act (as amended by section 102) (<external-xref legal-doc="usc" parsable-cite="usc/42/243">42 U.S.C. 243 et seq.</external-xref>) is further amended by inserting after section 318D the following:</text> 
<quoted-block act-name="" display-inline="no-display-inline" id="H9DB858785BBE4B4D94F3690609131087" style="traditional"> 
<section commented="no" display-inline="no-display-inline" id="H12DEA0A443D5429D89A7ABEF6FAEBCDB" section-type="subsequent-section"><enum>318E.</enum><header>Increasing public awareness of lupus and improving health professional education</header> 
<subsection commented="no" display-inline="yes-display-inline" id="HE8DE73FA901F4C5786A9E49B00B4C335"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary, acting through the Director of the Office on Women’s Health and in collaboration with the Lupus Foundation of America, Inc. and the National Center on Minority Health and Health Disparities of the National Institutes of Health, shall conduct and support a sustained national lupus public awareness and health professional education campaign, with an emphasis on reaching populations at highest risk for the disease.</text></subsection> 
<subsection commented="no" display-inline="no-display-inline" id="HB0AE8BB1092D4E4BA5AFE9006CDC3500"><enum>(b)</enum><header>Use of funds</header><text display-inline="yes-display-inline">In conducting the sustained national lupus public awareness and health professional educational campaign, the Director of the Office on Women’s Health shall—</text> 
<paragraph commented="no" display-inline="no-display-inline" id="H768C40ED18CB4784A98F6C4910FAFEAD"><enum>(1)</enum><text display-inline="yes-display-inline">promote increased awareness of early intervention and treatment so as to significantly improve the diagnosis, treatment, and quality of life for people with lupus;</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="H6DCB14E3CBB14D16ABBA51EEC8328FD"><enum>(2)</enum><text display-inline="yes-display-inline">direct communication and education efforts toward minority communities that may be underserved or disproportionately affected by lupus; and</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HC1C2F99020964BA48E28B8AC6409F259"><enum>(3)</enum><text display-inline="yes-display-inline">target at-risk women and health professionals likely to see women with lupus, including primary care physicians and specialists such as rheumatologists, nephrologists, dermatologists, and immunologists, so as to help reduce the amount of time taken to achieve a correct diagnosis of lupus.</text></paragraph></subsection> 
<subsection commented="no" display-inline="no-display-inline" id="HF1744C10C21049BCB8A75723D571CF21"><enum>(c)</enum><header>Certain activities</header><text display-inline="yes-display-inline">To the extent practicable and appropriate, the Secretary shall ensure that communications under subsections (a) and (b) provide the latest medically sound information related to the signs, symptoms, diagnosis, and disease management of lupus.</text></subsection> 
<subsection commented="no" display-inline="no-display-inline" id="HD04985EE1B684FF5935889E4331B17B"><enum>(d)</enum><header>Integration with other programs</header><text display-inline="yes-display-inline">To the extent practicable and appropriate, the Secretary shall integrate efforts under this section with other programs carried out by the Secretary.</text></subsection> 
<subsection commented="no" display-inline="no-display-inline" id="HFE7EFFC8006A46328BD3B97627FEFAB9"><enum>(e)</enum><header>Authorization of appropriations</header><text display-inline="yes-display-inline">There are authorized to be appropriated to carry out this section $1,000,000 for each of the fiscal years 2006 through 2010.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section></title> 
</legis-body> 
</bill> 

